Abraxane and Alimta in Advanced Solid Tumors

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel albumin-stabilized nanoparticle formulation together with pemetrexed may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with pemetrexed and to see how well they work in treating patients with advanced non-small cell lung cancer, breast cancer, or other solid tumors.

Detailed Description
-----------------
OBJECTIVES: Primary Determine the safety of paclitaxel albumin-stabilized nanoparticle formulation when administered with pemetrexed disodium in patients with advanced non-small cell lung cancer, breast cancer, or other solid tumors. (Phase I) Determine the efficacy of this regimen, as measured by objective tumor response rate (RECIST criteria), in these patients. (Phase II) Secondary Determine the preliminary efficacy of paclitaxel albumin-stabilized nanoparticle formulation and pemetrexed disodium in these patients. (Phase I) Determine the overall survival of patients treated with this regimen. (Phase II) Evaluate the frequency and severity of toxicities associated with this regimen. (Phase II) OUTLINE: This is a phase I, dose-escalation study of paclitaxel albumin-stabilized nanoparticle formulation followed by an open-label, phase II study. Phase I: Patients receive pemetrexed disodium IV over 10 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of paclitaxel albumin-stabilized nanoparticle formulation until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II: Patients receive pemetrexed disodium and paclitaxel albumin-stabilized nanoparticle formulation at the MTD as in phase I. After completion of study treatment, patients are followed periodically.

Official Title
-----------------
Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer

Conditions
-----------------
Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Intervention / Treatment
-----------------
* Drug: Abraxane
* Drug: Alimta


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria For the phase II portion patients must have cytologically or histologically proven selected stage IIIB (pleural effusion) or IV NSCLC. For the phase II portion patients must have NSCLC that has progressed or recurred after treatment with platinum-based therapy. No prior pemetrexed. Prior Taxol is allowed. Prior ABI 007 is not allowed. Patients must have measurable disease by RECIST criteria for the phase II portion. Patients must be 18 years of age or older. Patients must have a performance status of 0 -2 Patients must have an estimated survival of at least 3 months. Any prior chemotherapy must have been completed at least 4 weeks prior to start of treatment. Patients must have adequate renal function as documented by a calculated creatinine clearance of > 45 ml/min Patients must have adequate liver functions: AST and ALT < 2.5 X upper limit of normal, and bilirubin < upper limit of normal. Patients must have adequate bone marrow function: Platelets >100,000 cells/mm3 and ANC > 1,500 cells/mm3. For patients who have baseline clinically significant pleural or peritoneal effusions (on the basis of symptoms or clinical examination) before initiation of pemetrexed therapy, consideration should be given to draining the effusion prior to dosing. Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) may be included if they are neurologically stable and have been off steroids and anticonvulsants for at least 4 weeks. Patients must be able to take and retain oral medication. Ability to take folic acid, vitamin B12 and dexamethasone according to protocol. Ability to interrupt NSAIDS 2 days before, the day of, and 2 days following administration of pemetrexed. Patients of reproductive potential must agree to use effective contraceptive method while on treatment and for 3 months afterwards as the effects of these drugs on the unborn fetus are unknown. No other current active malignancy. Patient or his/her legally authorized representative or guardian signed the Informed Consent form prior to participation in any study-related activities. Exclusion Criteria Pregnant or breastfeeding women. Patient with pre-existing peripheral neuropathy of NCI CTCAE Version 3.0 of grade 2. Patient has a clinically significant concurrent illness. Patient is currently enrolled in a different clinical study in which investigational procedures are performed or investigational therapies are administered. Patient has a history of allergy or hypersensitivity to the study drugs or a taxane. Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug. Prior therapy with pemetrexed, or ABI-007. Patient is receiving treatment with any excluded concomitant medication. Presence of third space fluid which cannot be controlled by drainage.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Phase I: Abraxane and Alimta<br>Three dose levels were tested. Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, and 260 mg/m2 every 21 days. | Drug: Abraxane<br>* ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)<br>* Other names: ABI-007;Drug: Alimta<br>* Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)<br>* Other names: pemetrexed disodium;|
| Experimental: Phase II: Abraxane and Alimta<br>Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 260 mg/m2 every 21 days. | Drug: Abraxane<br>* ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)<br>* Other names: ABI-007;Drug: Alimta<br>* Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)<br>* Other names: pemetrexed disodium;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Dose Limiting Toxicities | Dose limiting toxicity (DLT) was defined as any of the following occurring during the first cycle: Grade 4 thrombocytopenia, or grade 3 thrombocytopenia associated with bleeding, requirement for transfusion, febrile neutropenia, neutropenia with documented infection. Non-hematologic DLT included any other ≥ grade 3 non-hematologic toxicity that was clinically significant and considered by the investigator to be related to study drug. Alopecia and grade 3 allergic reaction/hypersensitivity with infusion were not considered DLTs. | Up to21 days | 
| Number of Patients With Toxicities | Toxicities was evaluated based on the standard NCI CTCAE Version 3.0 grading criteria. Attributable grade ≥ 3 hematologic and non-hematologic toxicities are presented here. | Up to 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Overall Survival | From time of enrollment to the first observation of disease progression or death. | Up to 2 years | 
| Number of Participants With Complete Response | Per RECIST criteria, complete response (CR) is defined as the disappearance of all target lesions. | Up to 2 years | 
| Number of Participants With Stable Disease | Stable Disease is measured from the start of the treatment until the criteria for disease progression are met. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions | Up to 2 years | 
| Number of Participants With Partial Response | At least a 30% decrease in the sum of the longest diameter of target lesions | Up to 2 years | 
| Number of Participants With Disease Control | Disease control is complete response plus partial response plus stable disease from the start of treatment to death or disease progression. | Up to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
male breast cancer, recurrent breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IV breast cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, recurrent non-small cell lung cancer, unspecified adult solid tumor, protocol specific